MRK announces acquisition of Prometheus for $10.8B. The buyout price is to obtain drugs that have recently posted good results in stage 2 clinical trials for ulcerative colitis and Crohn's disease.

I have no expertise in evaluating or analyzing how a buyout price is ultimately determined, but even at an elementary level it strikes me that the potential revenue from an efficacious cancer drug would likely exceed (by several multiples) the market for treating these autoimmune indications and that the results obtained in LL's single arm cancer trials would be at least roughly comparable to stage 2 trial results. -- all of which causes me to wonder what good results in a stage 2 (or stage 3) LL/ Keytruda vs Keytruda trial might be worth?